Peptide and ‘human enhancement’ funds are joining a growing crowd of ETFs trying to capitalize off the wellness craze.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
ETFs tracking the performance of weight-loss drugs have largely underperformed since launching in late 2023.